NW-4-1231A

NW-4-1231A is a small molecule inhibitor of B-cell lymphoma 2 (Bcl-2) being developed by Guangzhou Lupeng Pharmaceutical (also known as Lupeng Bio). It is specifically targeted for the treatment of relapsed or refractory (R/R) B-cell malignancies. Bcl-2 is a pro-survival protein that is frequently overexpressed in various hematological cancers, where it plays a critical role in preventing apoptosis (programmed cell death). By selectively inhibiting Bcl-2, NW-4-1231A aims to restore the apoptotic process in malignant B-cells, thereby providing a therapeutic option for patients who have failed prior lines of therapy. The compound is part of Lupeng Bio's broader pipeline of hematology-focused therapies, which includes multiple generations of Bcl-2 inhibitors and protein degraders.